RESUMO
The overexploitation of fishmeal and soy for the feedstuff industry has provided an opportunity to employ insects as an unconventional and more environmental friendly protein source. The evaluation of the nutritive properties of different insect species has consequently become a priority. The present study compares the pupal nutritive composition of two silkworm strains (White Cocoon Polyhybrid and Golden Yellow Cocoon Nistari) fed on two different rearing media (fresh mulberry leaves and a commercial artificial diet). Our results provide evidence that the composition of the feeding substrate strongly influences the fat and protein content of silkworm pupae. The two tested strains had higher fat and lower protein contents when fed with silkworm natural food (mulberry leaves) with respect to the commercial artificial diet. The analysis also showed that the n3/n6 ratio was affected almost exclusively by the feed substrate factor. On the contrary, the carotenoid content in pupae was specifically determined by the strain. The study identifies the interesting opportunity offered by silkworm pupae, which are usually a waste product of the silk-reeling process, to be used as alternative animal protein sources in a fully-closed circular production.
RESUMO
PURPOSE: Active immunotherapy is a promising antitumoral strategy; however its use in combination with chemotherapy in dogs with large B-cell lymphoma (DLBCL) remains largely untested. Heat shock proteins (HSP) bind the small peptides they chaperone (HSPPC), allowing for immunization of the host against a large repertoire of tumor-associated antigens. Hydroxylapatite vehicles HSPPCs and acts as an immunologic adjuvant. The aim of this study was to show that an autologous vaccine with hydroxylapatite and tumor-derived HSPPCs is safe and therapeutically effective in dogs with DLBCL. EXPERIMENTAL DESIGN: Nineteen dogs with naturally occurring DLBCL were entered into a prospective randomized placebo-controlled double-blinded trial of HSPPCs-hydroxylapatite plus chemotherapy versus chemotherapy alone. Endpoints included time to progression (TTP), lymphoma-specific survival (LSS), and incidence of toxicoses. RESULTS: Median first TTP after randomization to the vaccine arm was 304 days versus 41 days for the control arm (P = 0.0004). There was also a statistically significant difference in duration of second remission between the two groups (P = 0.02). Median LSS was 505 days for the vaccinated dogs versus 159 days for the unvaccinated dogs (P = 0.0018). Six vaccinated dogs achieved molecular remission, as shown by clonal immunoglobulin H (IgH) rearrangement. Toxicoses were comparable between the two treatment arms. CONCLUSIONS: The results of this trial demonstrate that the autologous vaccine tested here is safe and efficacious in prolonging TTP and LSS in dogs with DLBCL when used in combination with dose-intense chemotherapy. On the basis of these results, additional evaluation of this novel therapeutic strategy is warranted in human DLBCL.